| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05536037 Details | 2024-04-19 Interventional | 1 | 4 | Metformin Erythroplasia Leukoplakia Precancerous Co… Erythroplakia Oral Cavity Car… Proliferative V… | Slow accrual - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT05411107 Details | 2024-04-19 Interventional | 2 | 0 | Iloprost Carcinoma Lung Diseases, … Lung Neoplasms Pulmonary Disea… Bronchial Epith… Chronic Obstruc… Lung Carcinoma Stage I Lung Ca… Stage II Lung C… Tobacco-Related… | Agent is not available - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT05213143 Details | 2024-04-19 Interventional | 4 | 13 | Lurasidone Hydr… Schizophrenia | Company's business decision - | |||
| NCT05040568 Details | 2024-04-19 Interventional | 1 | - | Cetuximab Cyclophosphamid… Fludarabine Fludarabine pho… Neoplasm, Resid… Colon Cancer Resected Stage | DMC Monitor Action - | |||
| NCT04949191 Details | 2024-04-19 Interventional | 2 | 10 | Pembrolizumab Neoplasms Advanced Malign… | A business decision due to availability of commercial drug and other options for accessing
study drug treatment. - | |||
| NCT04613518 2019-004878-26 Details | 2024-04-19 Interventional | 2 | 38 | Deucravacitinib Colitis Colitis, Ulcera… Ulcer | Trial terminated because of lack of efficacy in the short term acute phase. - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT04149574 Details | 2024-04-19 Interventional | 3 | 13 | BCG Vaccine Nivolumab Non-Muscle Inva… Urinary Bladder… | Insufficient enrollment, inability to meet protocol objectives, and slow accrual. - | |||
| NCT03801525 Details | 2024-04-19 Interventional | 2/3 | 277 | Venetoclax Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… Small Lymphocyt… | Strategic/Business decision Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. As such, the study results are reflective of the data captured to the time of study termination and with limited data verification. | |||
| NCT03474614 Details | 2024-04-19 Interventional | 2 | 4 | Propranolol Congenital Abno… Hemangioma, Cav… Cerebral Cavern… | lack of accrual - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT03186456 Details | 2024-04-19 Interventional | 1 | - | Aspirin Cerebral Infarc… Infarction | Others - | |||
| NCT03184935 Details | 2024-04-19 Interventional | 1/2 | - | Decitabine Myelodysplastic… Preleukemia Syndrome | Others - | |||
| NCT03176498 Details | 2024-04-19 Interventional | 1/2 | - | Aspirin Atorvastatin Calcium Cerebral Infarc… Infarction | Others - | |||
| NCT02875223 Details | 2024-04-19 Interventional | 1 | 75 | Itraconazole Pulrodemstat be… Rifampin Lymphoma Lymphoma, Non-H… Neoplasms | Business objectives have changed - | |||
| NCT02276911 Details | 2024-04-19 Interventional | 2 | 6 | Ibuprofen Opioid-Related … Pain, Postopera… Spondylosis Cervical Spondy… Lumbar Spondylo… | No enrollment - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT02085304 Details | 2024-04-19 Interventional | 1/2 | 8 | Temozolomide Glioblastoma | met stopping rules for futility - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT05432804 Details | 2024-04-18 Interventional | 1/2 | - | Temozolomide Glioblastoma Recurrence MGMT-Methylated… Recurrent Gliob… Recurrent MGMT-… | End of Initial Phase of Multi-phase protocol - | |||
| NCT05264974 Details | 2024-04-18 Interventional | 1 | - | Vaccines Melanoma Recurrence | major protocol revision in progress - | |||
| NCT05177718 Details | 2024-04-18 Interventional | 4 | 1 | Natalizumab Multiple Sclero… Sclerosis | Sponsor declined further support - | |||
| NCT05159531 Details | 2024-04-18 Interventional | 4 | 2 | Emtricitabine Tenofovir HIV Infections | Funding withdrawn - | 1 annotator(s) decided: DODTDSDWFUFRPIOC19 | ||
| NCT05104229 Details | 2024-04-18 Interventional | 3 | 0 | Aspirin Crohn Disease Thromboembolism Venous Thromboe… Ulcerative Coli… | Limited Resources - |